Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00151814 · ClinicalTrials.gov registry record · Phase 1

Olmesartan Pediatric Pharmacokinetic (PK) Study

A Phase 1 study of Hypertension, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
5
Study locations

NCT00151814 is a Phase 1 study of Hypertension that has completed, run by Daiichi Sankyo. The registered enrollment target is 24 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00151814, a Phase 1 study of Hypertension, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
5
Study locations

Study Summary

Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years

Conditions Studied

Hypertension

Interventions

  • DRUG Olmesartan medoxomil

Study Locations (5)

Arkansas

  • - Little Rock

California

  • - La Jolla

Kentucky

  • - Louisville

Missouri

  • - Kansas City

Ohio

  • - Cleveland

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2005-09
Est. Completion 2008-02
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00151814

The ClinicalTrials.gov registry entry for NCT00151814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Olmesartan medoxomil is the first listed.

NCT00151814 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00151814 about?

NCT00151814 is a clinical study titled "Olmesartan Pediatric Pharmacokinetic (PK) Study". Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years

What is the current status of trial NCT00151814?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-09. Estimated completion is 2008-02.

What conditions does trial NCT00151814 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00151814?

The interventions under investigation include: Olmesartan medoxomil (DRUG).

Who is sponsoring clinical trial NCT00151814?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00151814 being conducted?

This trial has 5 study locations across Arkansas, California, Kentucky, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.